NCT04961060RecruitingNot Applicable
Drivers of Eosinophilic COPD Exacerbations
University Medical Center Groningen2 sites in 1 country100 target enrollmentStarted: July 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 100
- Locations
- 2
- Primary Endpoint
- Change in gene expression profiles in nasal epithelium by using RNA sequencing
Study Overview
Brief Summary
Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes.
Detailed Description
Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes to better understand why some patients are more at risk for eosinophilic COPD exacerbations. Secondary objectives:
- Investigate differences in microbiome composition and immunophenotyping profiles in peripheral blood per subtype.
- Assess for clinical differences between all COPD exacerbation subtypes.
- Assess if and how baseline meta-transcriptomics either in nasal epithelium or sputum and blood immunophenotyping can be utilized to predict COPD exacerbation subtype.
- Determine if the microbiome in sputum and nasal epithelial material are comparable.
- Determine if different subtypes of COPD exacerbations respond differently to standard treatment with oral prednisolone (40 mg daily) with or without antibiotics.
- To evaluate if metabolic responses during recovery are different in patients with increased systemic inflammation compared to patients without systemic inflammation at exacerbation
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •COPD patient admitted to the hospital for an acute exacerbation of COPD
- •Physician diagnosed COPD according to the GOLD 2020 guidelines, including symptoms consistent with COPD, post-bronchodilator FEV1 < 80% predicted and FEV1/FVC < 70%.
- •Age > 40 years.
- •Smoker or ex-smoker, ≥ 10 pack years of smoking.
Exclusion Criteria
- •Current asthma, or prior physician diagnosis of asthma without a symptom- free interval of at least 10 years before the age of
- •Chronic use of prednisolone.
- •Use of systemic corticosteroids ≥4 days prior to hospital admission.
- •Necessity (upon hospitalization) for non-invasive ventilation or ICU admission.
- •Pneumonia at presentation documented by chest roentgenography.
- •Any other clinically relevant lung disease deemed to interfere with the concept of the study design.
- •Allergy to systemic corticosteroids or to antibiotics.
- •Females of childbearing potential without an efficient contraception unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH >40 mIU/mL or the use of one or more of the following acceptable methods of contraception:
- •Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).
- •Hormonal contraception (implantable, patch, oral, injectable).
- •Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository.
- •Continuous abstinence
- •Pregnancy or lactation.
- •Known immunodeficiency.
- •Life expectancy less than 60 days
Outcomes
Primary Outcomes
Change in gene expression profiles in nasal epithelium by using RNA sequencing
Time Frame: At admission and after 6-8 weeks after discharge.
Change in gene expression profilesin nasal epithelium between the four groups using RNA sequencing. The differences between the expression levels of transcripts (counts) will be analyzed.
Change in gene expression profiles in sputum by RNA sequencing
Time Frame: At admission and after 6-8 weeks after discharge.
Change in gene expression profiles in sputum between the four groups using RNA sequencing. The differences between the expression levels of transcripts (counts) will be analyzed.
Secondary Outcomes
- Microbiome composition in sputum by using RNA sequencing.(At admission, at day 5 of admission and 6-8 weeks after discharge.)
- Phenotype blood cell population by flow cytometry.(At admission, at day 5 of admission and 6-8 weeks after discharge.)
- Phenotypic analysis of the T cell compartment by staining of whole blood or isolated peripheral blood mononuclear cells using antibodies(At admission, at day 5 of admission and 6-8 weeks after discharge.)
- Clinical differences between groups by peak flow measurements.(Every day of hospital admission.)
- Comparison of microbiome composition in sputum and nasal epithelial material by RNA sequencing.(At admission and 6-8 weeks after discharge.)
- Clinical differences between groups by the COPD Assessment Test (CAT).(Every day of hospital admission.)
Investigators
Maarten van den Berge
Principal Investigator
University Medical Center Groningen
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Drivers of Eosinophilic COPD ExacerbationsNL-OMON54085niversitair Medisch Centrum Groningen100
Unknown
Not Applicable
Non-coding RNAs Analysis of Eosinophil Subtypes in AsthmaSevere Eosinophilic AsthmaAllergic AsthmaNCT04542902Lithuanian University of Health Sciences80
Recruiting
Not Applicable
Genetic analysis for eosinophilic sinusitis and construction of its databaseEosinophilic sinusitisJPRN-UMIN000039137Graduate School of Medical Sciences, Kyushu University Otorhinolaryngology60
Unknown
Not Applicable
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and AsthmaCOPD AsthmaEosinophilic AsthmaNCT05398133Medical University of Warsaw36
Completed
Not Applicable
Eosinophils Endotypes in Chronic Airway Inflammatory DiseasesEosinophilic AsthmaChronic SinusitisEosinophilic RhinitisNCT04187976University Hospital, Lille70